Media coverage about Sunshine Heart (NASDAQ:CHFS) has been trending somewhat negative this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunshine Heart earned a coverage optimism score of -0.01 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.4199508450171 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- CHF Solutions, Inc. (CHFS) Reaches $3.85 After 5.00% Up Move; RenaissanceRe Holdings Ltd. (RNR) Had 2 Analysts … – Hill Country Times (hillcountrytimes.com)
- CHF Solutions, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (finance.yahoo.com)
- Zacks Investment Research Lowers Sunshine Heart (CHFS) to Hold (americanbankingnews.com)
- Sunshine Heart (CHFS) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
Sunshine Heart (CHFS) traded up $0.31 during midday trading on Friday, reaching $3.89. 2,884,772 shares of the company’s stock traded hands, compared to its average volume of 388,486. Sunshine Heart has a fifty-two week low of $2.87 and a fifty-two week high of $137.00. The stock has a market cap of $6.99, a PE ratio of -0.03 and a beta of 2.25.
Several research firms have issued reports on CHFS. Zacks Investment Research cut shares of Sunshine Heart from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. ValuEngine upgraded shares of Sunshine Heart from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 31st.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/21/sunshine-heart-chfs-receiving-somewhat-critical-news-coverage-accern-reports.html.
About Sunshine Heart
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
Receive News & Ratings for Sunshine Heart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart and related companies with MarketBeat.com's FREE daily email newsletter.